By reprogramming glycolytic and lipid metabolic pathways, HKDC1 enhances invasiveness and chemoresistance., for example, in gastric cancer, where it drives cisplatin resistance alongside glycolysis up-regulation 23. This evidence concerns the gene HKDC1 and gastric cancer.